Since residual DA neurons in PD patients still conserve levels of NTSR1 [30–32] and TrkB [10], the NTS-polyplex-mediated BDNF gene therapy might be feasible and useful in the early stage of PD. This evidence concerns the gene NTSR1 and Parkinson disease.